Related Experiment Video
Updated: Sep 13, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
Published on: April 1, 2015
A rapid isocratic LC-MS/MS method for the quantification of busulfan in human plasma and its clinical application in
Ying Xia1, Yong Zhang1, Feng Chen1
1Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing, China. chenfeng18@njmu.edu.cn.
Abstract:
A rapid isocratic LC-MS/MS method for quantifying busulfan in human plasma was developed and validated. Plasma samples were processed by protein precipitation with acetonitrile using busulfan-d8 as the internal standard. Separation was performed on a Kinetex C18 column (2.1 × 50 mm, 5 µm; Phenomenex) with isocratic elution (water : acetonitrile = 70 : 30, v/v, containing 1 mM formic acid and 1 mM ammonium acetate) at 0.5 mL min-1, with a total run time of 1 min. Detection was conducted using positive electrospray ionization in multiple reaction monitoring mode (m/z 264.1 → 151.1 for busulfan; m/z 272.1 → 159.1 for busulfan-d8). The assay was linear over the concentration range of 0.100-10.0 µg mL-1 (r = 0.9998). Intra- and inter-batch RSD values were <5.5% and bias ranged from -3.6% to 5.0%. Recovery and matrix effect values were 100.1-101.3% and 101.4-101.8%, respectively. The method was successfully applied to 85 pediatric patients undergoing bone marrow transplantation. AUC0-∞ could be reliably estimated in 70 of the 85 patients (82.4%). Of these, 61.4% achieved the target AUC0-∞ (900-1500 µmol min L-1) after the first dose, while 18.6% fell below and 20.0% exceeded the target range, highlighting the substantial pharmacokinetic variability and the inadequacy of weight-based dosing in pediatric patients. This simple, rapid (1 min per sample) method is suitable for busulfan therapeutic drug monitoring in pediatric patients.
